Consensus Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
40.5 ^USD	+1.00%		+1.55%	-12.07%

Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
Mar. 08	Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Xenon Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

b97e524aa5524ef82.kCl-4rMlBpxMcfpx9-ZsWBjvujBaBB8QXRwRPycAdl8.p2MdiOF6dfI4HrVclNY9AEu9_mENVVdYHE0le1c1WzfBTCmthk5Z6wQbwg~501c1489293360326a273a51c21b09ad

Analyst Recommendations on Xenon Pharmaceuticals Inc.

Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating	Mar. 01	MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk	Mar. 01	MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating	Mar. 01	MT
Citigroup Initiates Xenon Pharmaceuticals With Buy Rating, Price Target is $62	Jan. 04	MT
Stifel Adjusts Price Target on Xenon Pharmaceuticals to $62 From $53, Maintains Buy Rating	Dec. 18	MT
Baird Initiates Xenon Pharmaceuticals With Outperform Rating, Price Target is $63	Dec. 08	MT
RBC Adjusts Xenon Pharmaceuticals' Price Target to $56 From $51, Maintains Outperform Rating	Nov. 28	MT
Wedbush Trims Xenon Pharmaceuticals' PT to $46 From $47, Says X-TOLE2 Enrollment Will Complete in H2 2024; Maintains Outperform Rating	Nov. 09	MT
Wedbush Raises Xenon Pharmaceuticals' Price Target to $47 From $44, Keeps Outperform Rating	23-05-10	MT
Cantor Fitzgerald Starts Xenon Pharmaceuticals at Overweight With $58 Price Target	23-04-25	MT
JPMorgan Adjusts Xenon Pharmaceuticals Price Target to $55 From $54, Maintains Overweight Rating	23-04-25	MT
Needham Adjusts Xenon Pharmaceuticals' Price Target to $50 From $48, Maintains Buy Rating	23-03-02	MT
Wedbush Lowers Xenon Pharmaceuticals' PT to $44 From $46, Shifts XEN1101 Launch Timing, Makes Near-Term Spending Adjustments; Keeps Outperform Rating	23-03-02	MT
RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confidence on Patents, Keeps Outperform Rating, Speculative Risk Qualifier	23-01-31	MT
Goldman Sachs Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $60 Price Target	22-12-14	MT
Cowen Starts Xenon Pharmaceuticals at Outperform	22-12-12	MT
Wells Fargo Initiates Xenon Pharmaceuticals With Overweight Rating, Price Target is $50	22-11-28	MT
Guggenheim Adjusts Price Target on Xenon Pharmaceuticals to $49 From $53, Maintains Buy Rating	22-11-11	MT
Wedbush Lowers Xenon Pharmaceuticals' Price Target to $46 From $50, Keeps Outperform Rating	22-11-09	MT
Raymond James Starts Xenon Pharmaceuticals at Outperform With $52 Price Target	22-10-19	MT
RBC Raises Price Target on Xenon Pharmaceuticals to $49 From $46, Maintains Outperform Rating, Speculative Risk Qualifier	22-10-11	MT
Xenon Pharmaceuticals Shares Rise After BofA Securities Initiates Coverage	22-08-29	MT
BofA Securities Initiates Coverage on Xenon Pharmaceuticals With Buy Rating	22-08-29	MT
SVB Securities Adjusts Xenon Pharmaceuticals' Price Target to $46 From $40, Keeps Outperform Rating	22-08-11	MT
RBC Raises Price Target on Xenon Pharmaceuticals to $46 From $41, Maintains Outperform Rating, Speculative Risk Qualifier	22-08-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.5 USD

Average target price

57.44 USD

Spread / Average Target

+41.83%

High Price Target

65 USD

Spread / Highest target

+60.49%

Low Price Target

45 USD

Spread / Lowest Target

+11.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Xenon Pharmaceuticals Inc.

Needham & Co.
RBC Capital Markets
Wedbush
Citigroup
Stifel Nicolaus
Baird
Cantor Fitzgerald
JPMorgan Chase
Goldman Sachs
Cowen
Wells Fargo Securities
Guggenheim
Raymond James
BofA Securities
SVB Securities LLC
Jefferies & Co.
SVB Leerink
SMBC Nikko

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar